Adaptive ensemble learning for prostate cancer classification on multi-modal MRI: reducing unnecessary biopsies

基于多模态磁共振成像的前列腺癌分类自适应集成学习:减少不必要的活检

阅读:1

Abstract

PURPOSE: This study aimed to develop and evaluate an adaptive weighted ensemble learning model using multiple CNN feature extractors for multi-modal MRI classification of PI-RADS 3-5 prostate lesions. The primary goal was to reduce unnecessary invasive biopsies while maintaining high diagnostic accuracy for prostate cancer detection. METHODS: A retrospective diagnostic accuracy study analyzed 196 patients (mean age 64 ± 8.5 years) with PI-RADS 3-5 lesions who underwent multiparametric MRI and biopsy between January 2023-November 2024. Five CNN feature extractors (MobileNet_v2, VGG16, DenseNet121, EfficientNet_b0, ResNet50) were compared within an adaptive weighted ensemble model integrating DCE, DWI, and T2-weighted sequences. The model incorporated expert architectures (CNN, Transformer, Attention LSTM) for each modality with dynamic weighting mechanisms. Performance was evaluated using 5-fold cross-validation with data augmentation and ADASYN balancing, comparing against histopathological reference standards and radiologist interpretations. RESULTS: VGG16 achieved the highest diagnostic accuracy (99.0 ± 0.7%, AUC 99.9 ± 0.1%), followed by MobileNet_v2 (97.5 ± 0.7%, AUC 99.7 ± 0.2%). The ensemble model demonstrated superior specificity compared to radiologists' biopsy recommendations for PI-RADS 3-5 lesions (98.9% vs. 0.0%) while maintaining high sensitivity (99.1% vs. 100%). Learned modality weights showed DCE contributed most significantly (41.6 ± 2.0%), followed by T2-weighted (33.9 ± 2.1%) and DWI (24.6 ± 1.6%) sequences. CONCLUSION: The proposed adaptive weighted ensemble model achieved superior diagnostic performance for prostate cancer classification compared to radiologist interpretation, demonstrating significant potential to reduce unnecessary biopsies while maintaining high sensitivity for cancer detection. These findings highlight the potential of the approach to improve the efficiency of prostate cancer diagnosis and support better clinical decision-making in prostate cancer management.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。